Lupus Treatment: From Hydroxychloroquine to Biologics

Lupus treatment relies on a layered combination of medications, starting with hydroxychloroquine as a near-universal backbone and adding corticosteroids, immunosuppressants, or biologics depending on which organs are affected and how severe the disease is. The landscape has shifted considerably in the past decade, with new targeted therapies offering more options for people who don’t respond to conventional drugs, and a strong push across guidelines to get patients off high-dose steroids as quickly as possible. No single drug controls every aspect of lupus, and treatment plans are highly individualized.

Hydroxychloroquine as the Foundation

Almost every person diagnosed with systemic lupus erythematosus (SLE) will be started on hydroxychloroquine, regardless of disease severity. Originally developed as an antimalarial, this drug has become so central to lupus care that most specialists consider it non-negotiable unless a patient has a specific contraindication. Hydroxychloroquine works by dampening several branches of the immune system at once: it interferes with the activity of compartments inside cells that process and recycle proteins, blocks certain immune sensors from detecting the body’s own DNA and RNA, and dials down the production of inflammatory signaling molecules called cytokines.¹ One particularly important effect is its ability to suppress interferon-alpha, a molecule that plays a central role in driving lupus activity, by blocking immune sensors in a specific type of immune cell.²

Beyond controlling symptoms, hydroxychloroquine reduces the risk of disease flares, protects against organ damage over time, and has even been linked to improved survival. It also carries metabolic benefits, including favorable effects on cholesterol and blood sugar. The drug is considered safe during pregnancy and breastfeeding, which matters a great deal since lupus disproportionately affects women of childbearing age.³

The Corticosteroid Dilemma

Corticosteroids like prednisone remain the fastest way to bring a lupus flare under control. They suppress inflammation broadly and effectively, and for serious organ involvement, they can be lifesaving. The problem is what happens when they stick around. Long-term steroid use causes weight gain, bone loss, high blood sugar, infections, cataracts, and cardiovascular damage, sometimes producing more harm than the disease itself. This has made steroid tapering one of the most important goals in modern lupus care.

How quickly you can taper matters. A study comparing tapering speeds found that stepping down slowly over twelve to twenty-four months cut the risk of flare by about 70% compared to trying to stop within three months.⁴ International consensus efforts have developed specific tapering schedules for mild, moderate, and severe lupus, recognizing that a one-size-fits-all approach doesn’t work.⁵

Adding biologic drugs early can help patients taper faster. In newly diagnosed patients, starting belimumab early was strongly associated with successfully reaching a low maintenance steroid dose within a year, with those patients roughly four times more likely to reach a low dose than those who didn’t receive it early.⁶ The bottom line: steroids still have a role, but treatment today is geared toward using them at the lowest dose for the shortest time.

Conventional Immunosuppressants

When lupus threatens a major organ, particularly the kidneys, stronger immunosuppressive drugs are needed. The two most established options for what’s called induction therapy (the initial aggressive phase of treatment) are mycophenolate mofetil and cyclophosphamide. For decades, cyclophosphamide was the go-to, but mycophenolate has increasingly taken its place as a first-line choice for many patients.

One landmark trial showed that mycophenolate was actually superior to cyclophosphamide for inducing complete remission in lupus nephritis, with about 23% of mycophenolate patients achieving complete remission versus roughly 6% on cyclophosphamide, along with fewer severe infections and hospitalizations.⁷ A larger follow-up trial found the response rates closer together (about 56% versus 53%) and failed to confirm superiority, though it confirmed that mycophenolate was at least as effective.⁸ The two drugs also differ in how they affect the immune system at a cellular level: mycophenolate is better at reducing certain antibody-producing cells in the blood, while cyclophosphamide tends to increase certain T cells and dendritic cells during the early months of treatment.⁹

Cyclophosphamide still has a role for the most severe cases, especially when patients don’t respond to mycophenolate, but its side-effect profile (including risks to fertility and increased cancer risk with cumulative exposure) means it’s used more cautiously than it once was. Azathioprine and methotrexate are other conventional options, typically reserved for milder organ involvement or as maintenance therapy after the initial aggressive phase.

Biologic Therapies

The approval of belimumab in 2011 marked the first new lupus drug in over fifty years. Belimumab is an antibody that targets a protein called B-lymphocyte stimulator, which fuels the survival and activity of B cells (the immune cells that produce the autoantibodies driving lupus).¹⁰ In phase 3 trials, patients receiving belimumab at the higher dose on top of standard therapy were significantly more likely to show meaningful improvement at one year compared to standard therapy alone, with response rates of roughly 43–58% versus 33–44% for placebo depending on the trial.¹¹¹² Those numbers may not sound dramatic, but in a disease as hard to treat as lupus, a consistent separation from placebo was a genuine milestone.

Anifrolumab, approved more recently, takes a different approach: it blocks the receptor for type I interferons, a family of signaling molecules overproduced in most lupus patients.¹³ By shutting down this signaling pathway, anifrolumab reduces the expression of a broad range of inflammatory genes and proteins, including those that activate innate immune cells and B cells.¹⁴ It has shown particular benefit for skin and joint manifestations.

Rituximab, which depletes B cells by targeting a different surface marker (CD20), occupies an unusual place in lupus treatment. Two large randomized trials failed to meet their primary endpoints.¹⁵ Yet in clinical practice, many rheumatologists have reported strong results, with roughly 80% of patients with severe, treatment-resistant disease showing marked improvement in open-label and real-world studies.¹⁶ Retrospective case series have also supported its use for relapsing and refractory lupus nephritis specifically.¹⁷ This gap between trial results and clinical experience is one of the enduring puzzles of lupus research, and it likely reflects how difficult it is to design lupus trials that capture the drug’s real benefits.

Voclosporin and Other Newer Additions

Voclosporin is a calcineurin inhibitor approved specifically for lupus nephritis. It works by suppressing the activation of T cells and also has a direct protective effect on podocytes, the specialized kidney cells that form the filtration barrier. This dual action makes it uniquely suited for kidney involvement.¹⁸ In its pivotal trial, 41% of patients receiving voclosporin on top of mycophenolate and low-dose steroids achieved a complete kidney response at one year, compared to 23% receiving mycophenolate and steroids alone.¹⁹

Current lupus nephritis guidelines from major organizations now reflect the trend toward early combination regimens, pairing drugs that work through different immune pathways. Belimumab or voclosporin can be layered on top of mycophenolate; obinutuzumab (another B-cell depleting antibody) is also being incorporated. These guidelines also emphasize kidney-protective strategies borrowed from chronic kidney disease management, such as blood pressure control and use of drugs that reduce protein in the urine.²⁰

CAR T-Cell Therapy on the Horizon

Perhaps the most exciting development in lupus treatment is the early results with CAR T-cell therapy, a technique borrowed from cancer treatment. In this approach, a patient’s own immune cells are collected, engineered in a laboratory to target B cells, and then infused back. The first published case series described five patients with severe, treatment-resistant lupus who all achieved drug-free remission within three months. Remarkably, remission persisted even after B cells reappeared in the blood months later.²¹

A broader pooled analysis covering 47 patients across ten studies found that about 81% achieved a low disease activity state. The most common side effect was cytokine release syndrome, which occurred in the vast majority of patients but was mild in almost all cases.²² These numbers are from early, uncontrolled studies, so the enthusiasm comes with appropriate caution. CAR T therapy is also expensive and logistically complex. But for people who have exhausted every other option, it represents a genuinely new category of treatment.

Treating the Skin

Cutaneous lupus, whether it occurs as part of systemic disease or on its own, follows a stepwise approach. Sun avoidance and broad-spectrum sunscreen are foundational, because ultraviolet light is one of the strongest known triggers for lupus skin flares.²³ For limited disease, topical corticosteroids or topical calcineurin inhibitors (non-steroid creams that calm the local immune response) are usually the first step.²⁴ When skin disease is widespread or doesn’t respond, hydroxychloroquine is the standard systemic therapy, followed by drugs like methotrexate, mycophenolate, dapsone, and in stubborn cases, thalidomide or its derivatives.

Neuropsychiatric Lupus

Lupus can affect the brain and nervous system, causing a wide range of symptoms from cognitive difficulties and headaches to seizures, psychosis, and stroke. This is one of the hardest aspects of the disease to manage, partly because it’s genuinely difficult to determine whether a neurological symptom is caused by lupus itself or by something else, like an infection, a medication side effect, or an unrelated neurological condition. There is no single diagnostic test that clinches it.²⁵

Treatment depends on the suspected underlying mechanism. When inflammation appears to be the driver, high-dose steroids and cyclophosphamide are the mainstay, with rituximab, intravenous immunoglobulins, or plasmapheresis as backup options. When the problem is thought to involve blood clots (common in patients with antiphospholipid antibodies), blood thinners become the primary therapy. Milder neuropsychiatric symptoms may be managed with azathioprine or mycophenolate.²⁶ Controlled trials specifically in neuropsychiatric lupus are scarce, so treatment decisions lean heavily on clinical judgment and experience from observational studies.²⁷

Hydroxychloroquine Eye Toxicity

The one serious long-term risk of hydroxychloroquine is damage to the retina. For a long time, this was thought to be rare, but better screening technology has revealed it’s more common than previously believed. Among patients who have taken the drug for more than five years, roughly 7.5% develop some degree of retinal toxicity, and the rate climbs to around 20% after twenty years of use.²⁸

The most important modifiable risk factor is daily dose relative to body weight. Taking more than 5 milligrams per kilogram of actual body weight substantially increases the risk, with one community study finding a hazard roughly three and a half times higher at that dose threshold.²⁹ Chronic kidney disease, female sex, and Asian ethnicity also raise the risk.³⁰ Current guidelines recommend annual eye exams starting after five years of use (or sooner for patients with additional risk factors). The damage, once advanced, is irreversible, so catching early changes on imaging is the key to prevention. Importantly, Asian patients may show a pattern of toxicity that’s missed by standard screening fields, so wider-field testing is recommended for that group.³¹

Cardiovascular Risk

People with lupus face a significantly elevated risk of heart attacks and strokes, driven by a combination of chronic inflammation, the metabolic effects of steroids, kidney disease, and the autoimmune process itself. Managing this risk is a legitimate pillar of lupus treatment, not just a side concern. Hydroxychloroquine itself appears to help by improving cholesterol and blood sugar levels.³² Statins may offer additional benefit beyond just lowering cholesterol: one study found that fluvastatin reduced disease activity scores, oxidative stress markers, and vascular inflammation in lupus patients within a month.³³ Current expert recommendations support prescribing statins for lupus patients who have elevated cardiovascular risk, applying principles from rheumatoid arthritis cardiovascular guidelines while awaiting lupus-specific trial data.³⁴

Exercise and diet also play meaningful roles. Systematic review evidence supports that physical exercise improves endothelial function (how well blood vessels relax and expand) in lupus patients, and low-calorie or low-glycemic-index diets may help obese patients with lupus reduce cardiovascular risk.³⁵

Monitoring Disease Activity

Tracking lupus over time relies on a combination of clinical assessment and blood tests. The most useful lab markers are anti-double-stranded DNA antibodies (anti-dsDNA) and complement proteins C3 and C4. In general, rising anti-dsDNA and falling complement levels signal increasing disease activity. A long-term prospective study found that significant rises in anti-dsDNA antibodies typically preceded clinical flares by about eight to ten weeks, making them a useful early warning system.³⁶

The correlation between these markers and disease activity is stronger for kidney flares than for flares affecting other organs. One study found that virtually all patients with active kidney involvement had elevated anti-dsDNA and low complement, whereas among patients with non-kidney flares, anti-dsDNA was elevated in only about a third.³⁷ This means abnormal labs in lupus should prompt concern, but normal labs don’t guarantee that everything is quiet, especially outside the kidneys.

Pregnancy Planning

Lupus doesn’t prevent pregnancy, but it does require careful medication management. Some commonly used lupus drugs are teratogenic and must be stopped before conception. Mycophenolate, methotrexate, and cyclophosphamide all carry risks of specific birth defects and should be discontinued before a planned pregnancy or as soon as pregnancy is recognized.³⁸ Hydroxychloroquine, on the other hand, should be continued throughout pregnancy and breastfeeding. Stopping it during pregnancy actually increases flare risk, and the drug does not appear to harm the fetus. Azathioprine and calcineurin inhibitors like tacrolimus are also considered compatible with pregnancy at standard doses, and prednisone is inactivated by the placenta, making it usable when needed for maternal disease control.

Breastfeeding is feasible for most lupus patients. A review of the available data found that the majority of lupus medications have minimal transfer into breast milk and are likely compatible with nursing.³⁹ The key is working with a rheumatologist to switch to pregnancy-safe medications well before conception, since some of the drugs that need to be stopped take time to clear the body.

Childhood-Onset Lupus

Children and adolescents diagnosed with lupus tend to have more aggressive disease than adults. They have a higher rate of kidney involvement from the outset, and their disease is more likely to cause serious organ damage early.⁴⁰ The medications used are largely the same as in adults, but most of them have never been formally studied in children through adequately powered trials, meaning treatment is based on extrapolation from adult data, consensus guidelines, and case series.⁴¹

Steroid side effects hit particularly hard in this age group because of their impact on growth and bone development. Fatigue, pain, and anxiety significantly affect quality of life in children with lupus, with these factors having a measurable impact on health-related quality of life scores independent of disease activity itself.⁴² The transition from pediatric to adult care is another vulnerable period, as patients may disengage from regular follow-up precisely when their disease is most dangerous.

Vaccinations and Infection Risk

Infection is one of the leading causes of death in lupus, partly because the disease itself impairs immune function and partly because the drugs used to treat it suppress the immune system further. Vaccination is therefore especially important, but it comes with caveats. Live vaccines are generally avoided in patients on significant immunosuppression. Inactivated and recombinant vaccines (like the flu shot, pneumococcal vaccine, and the newer recombinant shingles vaccine) are recommended, ideally administered during periods of low disease activity when vaccine responses are likely to be strongest.⁴³ Patients who have recently received B-cell depleting therapy (like rituximab) are unlikely to mount a good antibody response for months afterward, so timing vaccinations around treatment cycles is an important practical consideration.

Health Disparities in Lupus Outcomes

The advances in lupus treatment over the past several decades have not benefited all populations equally. Black patients with lupus have significantly lower life expectancy compared to White patients, and belonging to a racial or ethnic minority group has consistently been identified as a risk factor for more severe disease and worse outcomes.⁴⁴ Among Medicaid-enrolled lupus patients, Black patients had a 14% higher overall cardiovascular disease risk compared to White patients, with nearly 50% higher stroke risk. Hispanic patients also showed elevated stroke risk relative to White patients.⁴⁵

These gaps reflect a tangle of factors: genetic differences in disease severity, socioeconomic barriers to accessing care, difficulty affording medications, and historical underrepresentation in clinical trials that shape treatment guidelines. The newer biologic drugs are expensive, and access varies dramatically depending on insurance coverage and geography. Addressing these disparities is as much a part of improving lupus treatment as developing new molecules.

Fatigue and the Limits of Drug Therapy

Ask people with lupus what bothers them most, and fatigue often ranks near the top, sometimes above joint pain or rashes. It is one of the strongest predictors of poor quality of life, alongside depression and anxiety.⁴⁶ The frustrating reality is that fatigue often persists even when disease activity is well controlled on labs, suggesting it isn’t simply a matter of inflammation that hasn’t been treated aggressively enough.

Lifestyle interventions fill some of the gap that medications leave. A systematic review found that structured physical exercise improved fatigue, depressive symptoms, aerobic capacity, and physical functioning in lupus patients, while psychological interventions (like cognitive behavioral therapy) helped with depression, anxiety, and overall quality of life.⁴⁷ Photoprotection and consistent sunscreen use also reduce the frequency of flares. None of this replaces drug therapy, but it fills in areas where medications alone come up short. Lupus treatment, in the fullest sense, is a combination of pharmacology, vigilant monitoring, lifestyle adjustment, and a care team willing to revisit the plan as the disease evolves.

1
PubMed Central. Hydroxychloroquine in rheumatic autoimmune disorders and beyond ↩︎
2
PubMed. Hydroxychloroquine: a multifaceted treatment in lupus ↩︎
3
PubMed. Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception, Pregnancy and Breastfeeding ↩︎
4
Rheumatology. Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal ↩︎
5
Arthritis & Rheumatology. Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project ↩︎
6
PubMed. The Impact of Early Belimumab Use on Successful Glucocorticoid Tapering to a Low Maintenance Dose in Treatment-naïve, Newly Diagnosed Systemic Lupus Erythematosus ↩︎
7
PubMed. Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis ↩︎
8
PubMed Central. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis ↩︎
9
PubMed Central. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus ↩︎
10
PubMed Central. Belimumab in Systemic Lupus Erythematosus ↩︎
11
PubMed Central. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus ↩︎
12
The Lancet. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial ↩︎
13
Modern Rheumatology. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials ↩︎
14
Annals of the Rheumatic Diseases. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials ↩︎
15
PubMed Central. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design ↩︎
16
PubMed. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future ↩︎
17
Clinical Kidney Journal. Long-term B-cell depletion with rituximab in relapsing, refractory and severe lupus nephritis: a retrospective case series ↩︎
18
PubMed Central. Voclosporin: A comprehensive review of its role as a novel calcineurin inhibitor in the management of systemic lupus erythematosus ↩︎
19
The Lancet. Efficacy and safety of voclosporin for lupus nephritis (AURORA 1): a double-blind, randomised, phase 3 trial ↩︎
20
Oxford Academic (Nephrology Dialysis Transplantation). Comparative Analysis of Lupus Nephritis Guidelines: ACR 2025, EULAR 2025, and Kdigo 2024 ↩︎
21
Nature Medicine. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus ↩︎
22
PubMed Central. CAR T cell therapy efficacy and safety in SLE: a systematic review and pooled analysis of 47 patients across 10 studies ↩︎
23
PubMed Central. Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria ↩︎
24
PubMed Central. Treatment of cutaneous lupus ↩︎
25
PubMed Central. Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus ↩︎
26
PubMed Central. Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives ↩︎
27
PubMed Central. Neuropsychiatric Systemic Lupus Erythematosus: A 2021 Update on Diagnosis, Management, and Current Challenges ↩︎
28
PubMed Central. Hydroxychloroquine retinopathy ↩︎
29
Rheumatology. Risk of hydroxychloroquine retinopathy in the community ↩︎
30
PubMed Central. Risk of Retinopathy Associated with Long‐Term Use of Hydroxychloroquine in Patients with Rheumatic Diseases: A Systematic Review and Meta‐Analysis ↩︎
31
PubMed Central. Hydroxychloroquine retinopathy ↩︎
32
PubMed. Management of cardiovascular risk in systemic lupus erythematosus: a systematic review ↩︎
33
Annals of the Rheumatic Diseases. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment ↩︎
34
PubMed. Statins for prevention of cardiovascular disease in systemic lupus erythematosus ↩︎
35
PubMed. Management of cardiovascular risk in systemic lupus erythematosus: a systematic review ↩︎
36
PubMed. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study ↩︎
37
PubMed Central. Correlation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies ↩︎
38
PubMed. Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception, Pregnancy and Breastfeeding ↩︎
39
PubMed. Breastfeeding in mothers with systemic lupus erythematosus ↩︎
40
PubMed Central. The unique challenges of childhood-onset systemic lupus erythematosus and lupus nephritis patients: a proposed framework for an individualized transitional care plan ↩︎
41
PubMed Central. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus ↩︎
42
PubMed Central. Pain, Fatigue, and Psychological Impact on Health-Related Quality of Life in Childhood-Onset Lupus ↩︎
43
PubMed Central. Vaccination in systemic lupus erythematosus ↩︎
44
PubMed Central. Health disparities in systemic lupus erythematosus-a narrative review ↩︎
45
PubMed Central. Disparities in Lupus and Lupus Nephritis Care and Outcomes among U.S. Medicaid Beneficiaries ↩︎
46
PubMed. Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus ↩︎
47
PubMed Central. Efficacy of lifestyle interventions in the management of systemic lupus erythematosus: a systematic review of the literature ↩︎